Skip to main navigation menu Skip to main content Skip to site footer
FrancoAngeli Journals

Newsletter "Clinica dell'Alcolismo"

No. 47 (2016)

La terapia farmacologica dell’alcolismo: quali i limiti e le prospettive per l’implementazione dei trattamenti

Submitted
aprile 27, 2017
Published
2017-04-27

References

  1. Allen J.P., Wurst F.M., Thon N., Litten R.Z. (2013), “Assessing the drinking status of liver transplant patients with alcoholic liver disease”, Liver Transp., 19: 369-376.
  2. Anton R.F., Oroszi G., O’Malley S.S. et al. (2008), “An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioural Interventions for Alcohol Dependence (COMBINE) study”, Arch. Gen.
  3. Pharmacol.,65: 135-144.
  4. Brewer C., Myers R.J., Johnsen J. (2000), “Does disulfiram help to prevent relapse in alcohol abuse?”, CNS Drugs, 14: 329-341.
  5. Caputo F., Vignoli T., Tarli C., Domenicali M., Zoli G., Bernardi M., Addolorato G. (2016), “A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorders”, Int. J. Environ. Res. Public Health, 13: pii:E290.
  6. Center for Substance Abuse Treatment (2006), “Detoxification ans Substance Abuse Treatment. Treatment Improvement Protocol 45 (HHS Publication No. [SMA] 08-4131), Sunstance Abusr and Mental Health Services Administration, Rockville, MD.
  7. Center for Substance Abuse Treatment (2009), “Incorporating Alcohol Pharmacotherapies into Medical Practice. Treatment Improvement Protocol 49”, HHS Publication No. [SMA] 12-4389, Substance Abuse and Mental Health Services Administration, Rockville, MD.
  8. D’Amico E.J., Paddock S.M., Burnam A. et al. (2005), “Identification of an guidance for problem drinking by general medical providers: results from a national survey”, Medical Care, 43: 229-236.
  9. Fuller R.K., Gordis E. (2004), “Does disulfiram have a role in alcoholism treatment today?”, Addiction, 99: 21-24.
  10. Garbutt J. (2009), “The state of pharmacotherapy for the treatment of alcohol dependence”, Journal of Substance Abuse Treatment, 36: S15-S23.
  11. Harris A.H., Ellerbe L., Reder R.N., Bowe T., Gordon A.J., Hagedorn H., Oliva E., Lembke A, Kivlahan D, Trafton J.A. (2013), “Pharmacotherapy for alcohol dependence: perceived treatment for alcohol dependence: perceived treatment barriers and action strategies among veterans health administration service providers”, Psychol. Serv., 14: 410-419.
  12. Kahan M., Wilson L., Becker L. (1995), “Effectiveness of physicianbased interventions with problem drinkers: a review”, Canadian Med. Assoc. J., 152: 851-859.
  13. Kissack J.C., Bishop J., Roper A.L. (2008), “Ethylglucoronide as a biomarkers”, Clin. Lab., 59: 233-245.
  14. Krishnan-Sarin S., O’Malley S., Krystal J.H. (2008), “Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism”, Alcohol Res. Health, 31: 400-407.
  15. Laaksonen E., Koski-Jannes A., Salaspuro M. et al. (2008), “A randomized, multicenter, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence”, Alcohol, 43: 53-61.
  16. Litten R.Z., Bradley A.M., Moss H.B. (2010), “Alcohol biomarkers in applied settings: recent advances and future research opportunities”, Alcohol Clin. Exp. Res., 34: 955-967.
  17. Litten R.Z., Falk P., Ryan D.M., Fertig J. (2014), “Research opportunities for medications to treat alcohol dependence: addressing stake holders needs”, Alcohol Clin. Exp. Res., 38: 27-32.
  18. Lobstein T., Landon J., Thornton N., Jernigan D. (2016), “The commercial use of digital media to market alcohol products: a narrative review”, Addiction, doi: 10/1111/add. 13545.
  19. Martin B., Clapp L., Alfers J. et al. (2004), “Adherence to courtordered disulfiram at fifteen months: a naturalistic study”, J. Sub. Abuse Treat., 26: 233-236.
  20. National Institute on Alcohol Abuse and Alcoholism (2007), “Helping Patients Who Drink Too Much. A Clinician’s Guide, Updated 2005 Edition”, NIH Publication No. 07-3769, National Institute of Health, Bethesda, MD.
  21. Nava F., Premi S., Manzato E., Campagnola W., Lucchini A., Gessa G.L. (2007), “Gamma-hydroxxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam”, Am. J. Drug Alcohol Abuse, 33: 379-392.
  22. Office of Applied Studies (2014), “Results from the 2013 National Survay on Drug Use and Health: Summary of National Findings. Section 7.3, Alcohol Use Treatment and Tretment Need. NSDUH Series h-48 (HHS Publication No. [SMA] 14-4863”, Substance Abuse and Mental Health Services Administration, Rockville, MD.
  23. Rehn J. (2011), “The risk associated with alcohol use and alcohlism”, Alcohol Res. Health, 34: 135-143.
  24. Relazione del Ministro alla Salute al Parlamento sugli riservati ai sensi della Leggge 30.03.2001 n. 125 “Legge Quadro in Materia di Alcol e Problemi Alcol Correlati”.
  25. Sillanaukee P., Aalto M., Seppa K. (1998), “Carbohydrate-deficient transferrin and conventional alcohol marker sas indicators for brief intervention among heavy drinkers in primary health care”, Alcohol Clin. Exp. Res., 22: 892-896.
  26. Skipper G.E., Thon N., Dupont R.L., Baxter L., Wurst F.M. (2013), “Phosphatidylethanol: the potential role in further evaluating low positive urinary ethyl glucuronide and ethyl sulfate results, Alcohol Clin. Exp. Res., 37: 1582-1586.
  27. Solberg L.I., Maciosek M.V., Edwards N.M. (2009), “Primary care intervention to reduce alcohol misuse: ranking its health impact and cost effectiveness”, Am. J. Prev. Med., 34: 143-152.
  28. Substance Abuse and Mental Health Services Administration (SAMHSA) and National Institute on alcohol Abuse and Alcoholism (NIAA) (2012), “Report of the SAMHSA-NIAA Consensus Panel on New and Emerging Pharmacotherapies for Alcohol Use Disorders and Related Comorbidities”, Substance Abuse and Mental Health Services Administration, Rockville, MD.
  29. Topic A., Djukic M. (2013), “Diagnostic characteristics and application of alcohol biomarkers”, Clin. Lab., 59: 233-245.
  30. Volpicelli J.R., Watson N.T., King A.C. et al. (1995), “Effect of naltrexone on alcohol high in alcoholics”, Am. J. Psychiatry, 152: 613-615.
  31. Rubio G., Ponce G., Rodriguez-Jimenes R. et al. (2005), “Clinical redictior of response to naltrxone in alcohoics patients: who benefits most from treatment with naltrexone?”, Am. J. Addictions, 10: 258-268.
  32. Yersin B., Nicolet J.F., Dercrey H. et al. (1995), “Screening for excessive alcohol drinking: comparative value of carbohydratedeficient transferrin, gamma-glutamyltransferase, and mean corpuscolar volume”, Arch. Internal Med., 155: 1907-1911.
  33. Williams S.H. (2005), “Medications for treating alcohol dependence”, Am. Family Phys., 72: 1775-1780.

Metrics

Metrics Loading ...